Ocugen, Inc. (NASDAQ:OCGN) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET

Company Participants

Tiffany Hamilton - Head, Corporate Communications

Shankar Musunuri - Chairman, Chief Executive Officer and Co-Founder

Jessica Crespo - Chief Accounting Officer and Senior Vice President, Finance

Conference Call Participants

Jennifer Kim - Cantor

Jonathan Aschoff - ROTH Capital Partners

Daniil Gataulin - Chardan

Robert LeBoyer - Noble Capital Markets

Swayampakula Ramakanth - H.C. Wainwright

Operator

Good morning and welcome to the Ocugen Second Quarter 2022 Business Update and Financial Results Call. [Operator instructions] Please note that this call is being recorded. I will now turn the call over to Tiffany Hamilton, Ocugen’s Head of Corporate Communications. You may begin.

Tiffany Hamilton

Thank you, Samantha. Joining me today are Ocugen’s Chairman and CEO and Co-Founder, Dr. Shankar Musunuri, who will provide a business update and our Chief Accounting Officer and Senior Vice President of Finance, Jessica Crespo, who will provide more on our financial results.

Earlier this morning, we issued a press release detailing business activity for Q2 2022. We encourage listeners to review the press release, which is available on our website at ocugen.com. This call is being recorded and a replay along with the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are subject to risks and uncertainties. We may in some cases use terms such as predict, believe, potential, proposed, continue, estimate, anticipate, expect, plans, intend, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include, but are not limited to statements about the potential for NeoCart, chondrocyte-derived neocartilage, if approved to provide an innovative new option for the repair of full-thickness lesions of the knee cartilage in adults as well as Ocugen’s intention to begin dosing in Cohort 2 of the OCU400 clinical trial this month.

Such statements are subject to numerous important risks – excuse me factors, risks and uncertainties and may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are most fully described in our periodic filings with the Securities and Exchange Commission, SEC, including the risk factors described in the section entitled Risk Factors and the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of this presentation. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise after the date of this presentation. Finally, Ocugen’s second quarter 10-Q will be filed soon after today’s call.